Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + relatlimab fixed-dose combination with chemotherapy versus pembrolizumab with chemotherapy in first-line PD-L1-positive non-squamous metastatic or recurrent NSCLC
2024-513682-40-01Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of nivolumab, relatlimab, pembrolizumab, pemetrexed, carboplatin and 1 more in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Planned start Jul 2025; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513682-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513682-40-01.